Get the Stockscreener App
2.50
14.16%
0.31
Stereotaxis Inc stock is traded at $2.50, with a volume of 1.11M.
It is up +14.16% in the last 24 hours and up +14.16% over the past month.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to design and develop a next-generation magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.
See More
Previous Close:
$2.19
Open:
$2.3
24h Volume:
1.11M
Relative Volume:
2.82
Market Cap:
$215.00M
Revenue:
$25.14M
Net Income/Loss:
$-21.57M
P/E Ratio:
-9.2593
EPS:
-0.27
Net Cash Flow:
$-12.23M
1W Performance:
+12.61%
1M Performance:
+14.16%
6M Performance:
+2.88%
1Y Performance:
+35.14%
1-Day Range:
$2.29
$2.565
1-Week Range:
$2.18
$2.565
52-Week Range:
$1.54
$2.7155
Stereotaxis Inc Stock (STXS) Company Profile
Name
Stereotaxis Inc
Sector
Industry
Phone
314-678-6100
Address
4320 Forest Park Avenue, Suite 100, St. Louis, MO
Compare STXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STXS
Stereotaxis Inc
|
2.50 | 203.06M | 25.14M | -21.57M | -12.23M | -0.27 |
|
ISRG
Intuitive Surgical Inc
|
470.08 | 169.94B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
193.50 | 49.41B | 21.39B | 1.59B | 2.55B | 5.56 |
|
RMD
Resmed Inc
|
283.90 | 41.12B | 5.15B | 1.40B | 1.65B | 9.51 |
|
ALC
Alcon Inc
|
85.75 | 41.61B | 9.93B | 1.12B | 1.58B | 2.25 |
|
WST
West Pharmaceutical Services Inc
|
240.98 | 17.06B | 2.90B | 467.20M | 306.90M | 6.37 |
Stereotaxis Inc Stock (STXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-24 | Initiated | ROTH MKM | Buy |
| Jul-12-22 | Initiated | Aegis Capital | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Jan-05-22 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | Loop Capital | Buy |
| May-26-21 | Initiated | Piper Sandler | Overweight |
| Sep-08-20 | Initiated | Northland Capital | Outperform |
| Apr-09-20 | Initiated | Cowen | Outperform |
| Apr-07-20 | Initiated | Lake Street | Buy |
View All
Stereotaxis Inc Stock (STXS) Latest News
Stereotaxis: Pioneering the Future of Robotic Cardiology Amid Strategic Momentum - AInvest
Does Stereotaxis Inc. show high probability of reboundFree Weekly Watchlist of High Movers - Newser
Stereotaxis reiterates double-digit revenue growth outlook for 2025 as new catheter launches drive commercial momentum - MSN
Forecasting Stereotaxis Inc. price range with options dataFree Day Trading Signals With High Precision - Newser
Intraday pattern recognizer results for Stereotaxis Inc.Strong Buy Signal Summary with Entry Zone - Newser
Historical volatility pattern of Stereotaxis Inc. visualizedFree Daily Smart Money Movement Monitor - Newser
Regression analysis insights on Stereotaxis Inc. performanceFree Triple Digit Growth Focused Trade Plan - Newser
What makes Stereotaxis Inc. stock price move sharplyBuy and Hold Position Summary Review - Newser
Should I buy Stereotaxis Inc. stock before earningsFree Weekly Setup With 3x Return Potential - Newser
Stereotaxis Reports Double-Digit Revenue Growth for 2025 Amidst New Catheter Launches - AInvest
Stereotaxis (STXS): A Robotics-Driven Inflection Point in 2025 - AInvest
Is Stereotaxis Inc. a Top Dividend Stock to Watch in 2025Buy Candidate Summary Based on Fundamentals - Newser
Earnings call transcript: Stereotaxis Q2 2025 revenue beats forecasts By Investing.com - Investing.com Nigeria
Earnings call transcript: Stereotaxis Q2 2025 revenue beats forecasts - Investing.com
Best data tools to analyze Stereotaxis Inc. stockFree Weekly Hot Picks With Buy Confidence - Newser
Stereotaxis Inc. recovery potential after sell offLow Risk Trade Timing with Analysis Metrics - Newser
Stereotaxis Q2 2025 Earnings: Revenue Surges to $8.8 Million, EPS of -$0.05 Beats Estimates. - AInvest
Stereotaxis Inc (STXS) Q2 2025 Earnings Call Highlights: Impressive Revenue Surge and Strategic Advancements - GuruFocus
Stereotaxis reports Q2 EPS (5c), consensus (6c) - TipRanks
Stereotaxis Inc. (STXS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Stereotaxis earnings beat by $0.02, revenue topped estimates - Investing.com Canada
Unlocking Value in Stereotaxis: A High-Growth Medical Tech Play in a Resilient Sector - AInvest
Stereotaxis Reports 2025 Second Quarter Financial Results - GlobeNewswire
Stereotaxis Reports Massive 95% Revenue Jump as New FDA-Cleared Robotic Catheter Drives Growth - Stock Titan
Will Stereotaxis Inc. see short term momentumAI Generated Momentum Stock Forecast Guide - Newser
Does Stereotaxis Inc. stock perform well during market downturnsUnbelievable profit margins - Jammu Links News
What drives Stereotaxis Inc. stock pricePhenomenal returns - Jammu Links News
How strong is Stereotaxis Inc. company’s balance sheetAccelerated investment success - Jammu Links News
What are analysts’ price targets for Stereotaxis Inc. in the next 12 monthsUnprecedented profit potential - Jammu Links News
Should I hold or sell Stereotaxis Inc. stock in 2025Maximize returns with disciplined trading - Jammu Links News
How does Stereotaxis Inc. compare to its industry peersInvest confidently with proven investment plans - Jammu Links News
Stereotaxis Inc. Stock Analysis and ForecastDynamic profit expansion - Jammu Links News
What is Stereotaxis Inc. company’s growth strategyRapidly growing investment returns - Jammu Links News
Is Stereotaxis Inc. a growth stock or a value stockMaximize returns with strategic stock selection - Jammu Links News
What institutional investors are buying Stereotaxis Inc. stockFree Buy/Sell Signal Notifications - Jammu Links News
Trendlines Suggest Stereotaxis Inc. May Bottom Out SoonAccurate Buy Point for Momentum Stocks Detected - metal.it
Stereotaxis Inc.’s volatility index tracking explainedFree Reliable Alerts for Daily Stock Movers - Newser
What are Stereotaxis Inc. company’s key revenue driversAI Powered Growth Plan For 2025 - Jammu Links News
Monogram robot marks autonomy milestone; Stereotaxis catheter cleared - MedTech Dive
Stereotaxis Inc. Q2 Earnings Preview: Revenue Up 76.7%, EPS Unchanged - AInvest
Will Stereotaxis Inc. (STXS) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Is Stereotaxis Inc. stock bottoming outReliable Alerts for Daily Stock Movers Released - metal.it
Why did STXS revenue surge in Q3 2024 despite rising expenses? - AInvest
How does Stereotaxis Inc. generate profit in a changing economySwing Trade Entry Points For Fast Growth - jammulinksnews.com
Navigating STXS’s Stock Market Maze: Ups and Downs in 2025 - investchronicle.com
Stereotaxis' MAGiC Sweep: A Strategic Inflection Point in Robotic Electrophysiology - AInvest
Stereotaxis wins FDA clearance for diagnostic mapping catheter - Yahoo Finance
Stereotaxis' FDA-Cleared MAGiC Sweep Catheter: A Catalyst for Growth in the Robotic Ablation Era - AInvest
Stereotaxis Wins FDA Nod for MAGiC Sweep EP Catheter - Medical Product Outsourcing
Stereotaxis stock soars after FDA clearance for robotic mapping catheter By Investing.com - Investing.com Canada
Stereotaxis receives FDA clearance for robotic mapping catheter By Investing.com - Investing.com Nigeria
Stereotaxis Inc Stock (STXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):